"Drug Monitoring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.
| Descriptor ID |
D016903
|
| MeSH Number(s) |
E01.370.520.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Monitoring".
Below are MeSH descriptors whose meaning is more specific than "Drug Monitoring".
This graph shows the total number of publications written about "Drug Monitoring" by people in this website by year, and whether "Drug Monitoring" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 3 | 3 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 2 | 5 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 1 | 2 |
| 2021 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Monitoring" by people in Profiles.
-
Eliminating HIV transmission through breast milk from women taking antiretroviral drugs. BMJ. 2021 09 29; 374:n1697.
-
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. Lancet Child Adolesc Health. 2021 09; 5(9):642-651.
-
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. PLoS Med. 2021 06; 18(6):e1003670.
-
Performance of Cepheid Xpert HIV-1 viral load plasma assay to accurately detect treatment failure. AIDS. 2019 10 01; 33(12):1881-1889.
-
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019 03; 7(3):249-259.
-
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 11; 15(11):e1002690.
-
Validation of the Mission® PTCoagulation Monitoring point-of-care device for the outpatient management of patients on long-term warfarin therapy. Int J Lab Hematol. 2018 08; 40(4):e71-e73.
-
Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy. AIDS. 2018 01 28; 32(3):357-361.
-
Lamivudine monotherapy in children and adolescents: The devil is in the detail. S Afr Med J. 2017 Nov 27; 107(12):1055-1057.
-
Diagnosis and monitoring of HIV programmes to support treatment initiation and follow up and improve programme quality. Curr Opin HIV AIDS. 2017 03; 12(2):117-122.